Keywords: sr, pharma, loss, up, after, atugen, buy
SR Pharma's 2005 loss up 20% after Atugen buy
Article | 03 July 2006
London, UK-headquartered drugmaker SR Pharma says that, for full-year 2005, its pretax losses deepened 20% on the previous year, to L3.6 million ($6.5 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
